Diagnostic efficacy of monocyte distribution width to high-sensitivity C-reactive protein ratio in differentiating pathogen types in community-acquired pneumonia: a retrospective cohort study
Abstract
Abstract Objectives Community-acquired pneumonia (CAP) remains a diagnostic challenge in emergency departments, where rapid and accurate pathogen differentiation is essential for appropriate antimicrobial therapy and stewardship. Current biomarkers demonstrate limited accuracy in distinguishing bacterial from viral and atypical pathogens, necessitating novel diagnostic approaches. This study aimed to assess the diagnostic accuracy of the monocyte distribution width to high-sensitivity C-reactive protein ratio (MDW/hs-CRP) for differentiating bacterial, viral, atypical, and mixed community-acquired pneumonia (CAP) pathogens. Methods This retrospective cohort study enrolled 486 adult patients with radiologically confirmed CAP in an emergency department (Jan 2023–Dec 2024). Pathogens were identified using comprehensive microbiological testing. MDW was measured via automated hematology analyzer (Beckman Coulter DxH900); hs-CRP via standard assays. The primary outcome compared the MDW/hs-CRP ratio’s diagnostic accuracy to individual biomarkers using ROC analysis (DeLong test), Youden index (cutoff), decision curve analysis (DCA), and subgroup analyses. Results Pathogen distribution: 198 (40.7 %) bacterial, 142 (29.2 %) viral, 89 (18.3 %) atypical, 57 (11.7 %) mixed. For distinguishing bacterial from viral CAP, the MDW/hs-CRP ratio significantly outperformed MDW alone (AUC 0.752) and hs-CRP alone (AUC 0.798), achieving an AUC of 0.893 (95 % CI: 0.865–0.921; p<0.001). The optimal…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 486 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.